About: pharmaceutical strategy
New EU’s pharma rules: a game-changer for strategic autonomy on plasma?
Ensuring sufficient plasma collection in Europe remains a thorny issue but the forthcoming revision of the EU framework for pharmaceuticals offers the potential to turn the tide.
Europabio: Life science needs future-proof approach to become innovation ‘powerhouse’
The EU's policy priorities are a once-in-a-generation change to the regulatory framework offering both the industrial biotech and healthcare sectors an opportunity to set a direction for the next decades, says the newly appointed chairman of EuropaBio.
Pharma rules overhaul steals scene of EU’s 2022 health agenda
The revision of the legislative framework of pharmaceuticals and of medicines for children and rare diseases will drop the curtain on next year's Commission agenda as they are expected to be adopted in December 2022.
EU action to turn the AMR tide looks at different incentive models
EU policymakers are being urged to consider the full range of new incentive systems and pilot innovative approaches to tackle antimicrobial resistance (AMR), including Netflix-style subscription services and pull incentives.
If we forcibly remove patents on vaccines, we are killing a golden industry
Instead of being sidetracked by the debate on waiving patents on COVID vaccines, the EU must come up with a new pharma strategy and strengthen its pharmaceutical industry, writes Pernille Weiss.
COVID-19 plasma therapy comes handy either way, EU Commission says
Even though the efficiency of plasma therapies against COVID-19 are not yet demonstrated, increasing Europe's blood collection capacity will contribute to address chronic shortages, the European Commission has said.
Pharmaceutical Strategy must do more to support nanomedicines
The EU’s Pharmaceutical Strategy must do more to support nanomedicines and protect patient safety. Here’s why. Mike Isles is the Executive Director of the European Alliance for Access to Safe Medicines (EAASM). If Europe is to make its world-leading pharmaceutical...
Commission slows down on returning drug manufacturing to Europe
Despite widespread hopes for a quick shift towards 'strategic autonomy', the European Commission has made clear it needs another two years of reflection before coming up with proposals to reduce the risk of shortages caused by over-reliance on third-country medicine production.
EU ponders new incentives for novel antibiotics
The European Commission will examine specific incentives and a new pricing system to develop innovative antibiotics in its pharmaceutical strategy, in a bid to take a more ambitious stance against the rising threat of anti-microbial resistance (AMR).
Report: Without orphan drugs law, 2mn patients deprived access to therapies
In the absence of the EU orphan drugs regulation, which focuses on rare diseases, approximately two million patients would not get access to therapies, a new industry-funded report has found.
EU health agenda: More than Corona
The EU executive is expected to finally get to the heart of its five-year health agenda with the unveiling of Europe's Beating Cancer Plan and the much-awaited pharmaceutical strategy. The launch of both initiatives was confirmed for the fourth quarter of 2020 in the Commission's latest working programme.
The complexity of R&D for orphan medicines
There are multiple challenges inherent to drug development for rare diseases, all consequences of the small number of patients. For most of these diseases, the body of pre-existing knowledge is extremely limited with a lack of crucial information such as...
From pandemic to rare disease, medical innovation is the answer
Living through a global pandemic, we can take some comfort from the enormous collaborative research and development response that is taking place to find a way out from under the shadow of the COVID-19 crisis. Scientists around the world are...
EURORDIS: Rare diseases need more centralised processes within the EU
Future improvement of the EU Orphan Medicines Regulation (OMP) could involve more centralised processes for all rare diseases at the EU level, the European Organisation for Rare Diseases (EURORDIS) told EURACTIV in a written interview.
Commission’s ‘risky’ move to re-visit orphan drugs regulation
The European Commission is expected to present by the end of July an evaluation study on the pros and cons of the application of orphan and paediatric regulations, which deal with a niche segment of rare diseases that affect fewer than five in 10,000 people.